These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15055276)

  • 1. Bisphosphonate and estrogen replacement therapy for postmenopausal periodontitis.
    Haimov-Kochman R; Kochman T; Stabholz A; Hochner-Celinkier D
    Isr Med Assoc J; 2004 Mar; 6(3):173-7. PubMed ID: 15055276
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonate addition to stable hormone replacement therapy increases bone mineral density in postmenopausal women.
    Boulos P; Sebaldt RJ; Goldsmith CH
    J Rheumatol; 2002 May; 29(5):1110-1. PubMed ID: 12022339
    [No Abstract]   [Full Text] [Related]  

  • 3. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Estrogen replacement therapy in osteoporosis].
    Hirvonen E
    Duodecim; 1996; 112(22):2123-9. PubMed ID: 10605218
    [No Abstract]   [Full Text] [Related]  

  • 5. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periodontitis in estrogen-deficient women.
    Daniell HW
    Arch Intern Med; 2002 Dec 9-23; 162(22):2634-5; author reply 2635. PubMed ID: 12456249
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T
    Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance with drug therapies for the treatment and prevention of osteoporosis.
    McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
    Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective strategies to identify postmenopausal women at risk for osteoporosis.
    Levine JP
    Geriatrics; 2007 Nov; 62(11):22-30. PubMed ID: 17999567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
    Book C; Karlsson M; Akesson K; Jacobsson L
    Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
    Grady D; Vittinghoff E; Lin F; Hanes V; Ensrud K; Habel LA; Wallace R; Macer J; Cummings SR; Shepherd J
    Menopause; 2007; 14(3 Pt 1):391-6. PubMed ID: 17224859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
    Barton M; Meyer MR; Haas E
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1669-72. PubMed ID: 17634518
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-response to osteoporosis treatment.
    Francis RM
    J Br Menopause Soc; 2004 Jun; 10(2):76-80. PubMed ID: 15207030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.